Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis Lays A New Foundation In Prostate Cancer With Second Radioligand Launch

Executive Summary

"We have big plans," oncology president Susanne Schaffert said in an interview about launching Pluvicto, its new radioligand therapy for prostate cancer.

You may also be interested in...



Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: Novartis builds radioligand therapy franchise; BMS pioneers new checkpoint inhibitors; Russian CRO leader tries to keep Ukraine trials going; Indian pharma and celebrity endorsement; and how R&D spend compares to 10 years ago.

Keeping Track: Pluvicto Boosts Novartis In Radiotherapy; BMS Builds Out IO Estate With Opdualag

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Novartis Poised To Grow Despite $9bn In LOEs Coming, CEO Says

CEO Vas Narasimhan committed to delivering compound annual growth of 4% from 2020-2026, driven by newer brands plus some pipeline assets.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC145849

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel